<li>Diabetes Pathophysiology</li>
 <li>Glucagon-Like Peptide-1 Mechanisms</li>
<p>

</p>

Diabetes Pathophysiology Glucagon-Like Peptide-1 Mechanisms

Pathophysiologic Targets

In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and their own experience, cardiologist Jorge Plutzy, MD, and endocrinologist Helena Rodbard, MD, navigate through a series of ‘clinical questions’ to inform regarding the clinical pharmacology of the GLP-1RAs and their evidence-based role in cardiovascular risk reduction, particularly in patients with secondary atherosclerotic cardiovascular disease.

Share Pathophysiologic Targets

Sign up to save your podcasts

Pathophysiologic Targets

Pathophysiologic Targets